ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Arbutus Biopharma Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$4.23+0.01 (+0.24%)

Close on Oct 19, 2026

Market cap: $835.30M
P/E (TTM): 5.4
Dividend yield: –

Arbutus Biopharma Corp balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Cash & Equivalents	18	36	26	31	109	52	32	37	54	23	167	72	69	47	9.03	12
Short-Term Investments	73	86	100	116	46	71	59	88	72	107	15	40	–	–	–	–
Cash & Short-Term Investments	92	123	132	184	191	123	91	125	126	131	181	112	0.07	47	9.03	12
Receivables	1.45	2.41	1.78	1.35	0.90	1.31	1.20	1.43	0.40	0.27	1.01	1.90	0.12	1.07	–	–
Prepaid Expenses & Other	1.54	2.28	4.25	2.87	4.45	3.12	1.79	3.18	2.14	1.31	1.20	1.73	1.08	–	–	–
Total Current Assets	94	127	132	151	161	128	94	129	129	133	184	116	70	–	–	–
Property, Plant & Equipment	0.03	3.31	4.67	5.07	5.98	6.93	8.68	10	12	6.95	3.18	1.76	1.37	–	–	–
Gross Property, Plant & Equipment	0.25	16	17	16	15	15	14	17	25	18	13	13	13	–	–	–
Accumulated Depreciation	-0.21	-13	-12	-11	-9.37	-7.62	-5.64	-6.90	-13	-11	-9.73	-11	-12	–	–	–
Long-Term Investments	0	0	6.28	37	36	0	0	–	0	0	10	0	–	–	–	–
Equity Method Investments	0	0	0	0	0	0	0	22	0	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0	1.05	1.42	1.74	2.09	2.41	2.74	0	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	–	–	0	22	24	24	163	0	–	–	–	–
Intangible Assets	–	–	–	–	–	–	0	44	59	99	353	0	–	–	–	–
Other Long-Term Assets	0.13	0.03	0	0.10	0.06	0.04	0.29	0	–	–	–	–	–	–	–	–
Total Assets	95	132	144	195	204	137	106	228	237	276	712	118	72	–	–	–
Accounts Payable	5.46	7.56	10	16	11	9.15	7.24	9.43	11	9.91	8.83	9.33	3.68	–	–	–
Current Portion of Leases	0.55	0.48	0.43	0.37	0.38	0.39	0.34	0	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	0	7.57	12	16	0	–	–	0	2.74	0.02	0.87	5.78	3.46	–	–	–
Total Current Liabilities	6.01	16	22	33	11	9.54	7.83	11	15	11	11	20	13	–	–	–
Long-Term Leases	0.20	0.81	1.34	1.82	2.23	2.59	3.02	0	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0.75	1.29	1.77	2.19	2.61	2.98	3.36	0	–	–	–	–	–	–	–	–
Deferred Tax Liabilities	–	–	–	–	–	–	0	13	17	41	146	0	–	–	–	–
Total Liabilities	18	34	38	59	35	35	33	28	55	73	165	30	13	–	–	–
Preferred Stock	–	–	–	–	–	–	–	–	49	–	–	–	–	–	–	–
Common Stock	1,421	1,410	1,350	1,319	1,287	986	899	879	876	867	834	290	217	–	–	–
Additional Paid-In Capital	83	82	81	72	65	61	55	48	43	37	30	26	25	–	–	–
Retained Earnings	-1,380	-1,347	-1,277	-1,204	-1,134	-1,046	-970	-805	-738	-653	-267	-206	-167	–	–	–
Comprehensive Income & Other	-48	-48	-48	-50	-48	-48	-48	-48	-48	-48	-50	-22	-16	–	–	–
Shareholders' Equity	77	97	106	137	169	102	73	200	182	203	548	88	59	41	5.23	11
Total Equity	77	97	106	137	169	102	73	200	182	203	548	88	59	41	5.23	11
Total Liabilities & Equity	95	132	144	195	204	137	106	228	237	276	712	118	72	–	–	–
Shares Outstanding(shares)	193	190	170	157	145	90	65	56	55	55	55	22	19	14	12	10

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 82.0%
Net margin: 84.2%
Return on equity, FY2025: -38.5%

Financial strength

Current ratio: 81.42
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 569.9%

Valuation

P/E ratio: 5.4
Price to sales: 4.60
Price to book: 3.23
Dividend yield: –